견적문의

NEW YORK--( / )--Dentsu Aegis Network today announces that it has acquired the global B-to-B digital media and marketing agency, DWA. The deal is the latest addition to the group’s B-to-B capability, following the acquisition of gyro last year and BAND in 2015.

The move will expand the B-to-B offering at people-based marketing agency, Merkle, adding scale and breadth to existing capabilities and offering brands in the technology and B-to-B sectors greater sophistication, integrated technology, data, creativity, and outstanding performance marketing. The new business will be branded “DWA, a Merkle company”.

DWA applies expertise in ad-tech, real-time insight, and management decision support to a range of integrated, global media including: Programmatic, Search, Social, and Demand Generation. Its approach has delivered success for a diverse group of enterprise clients, including Sprint, NetApp, Cisco, DXC, Salesforce, Oracle, and Informatica.

“I’m thrilled to see Merkle recognize DWA’s strengths and dedication to B-to-B technology, and excited to see what our next chapter will bring as we join forces with the global leader in one-to-one marketing,” said David Wood, Founder of DWA. “DWA has a proud history of activating data-driven, digital campaigns for some of the highest regarded B-to-B technology brands in the world. We believe that we are at the forefront of a new advertising generation that focuses on delivering more valuable connections through people-based marketing, and we’ve found a valuable partner who shares our vision and augments our capabilities in Merkle.”

Established in 1996, DWA is headquartered in San Francisco, with eight additional offices around the world. All 150+ employees will join Merkle’s High Tech and B-to-B practice.

“There’s a growing group of enterprise level, B-to-B and technology businesses, all moving at breakneck pace to adopt the best advertising solutions and platforms. DWA’s client list reflects a clear early-mover advantage,” said David Williams, President and CEO, Merkle. “The shift toward people-based marketing, led by Merkle, is as relevant in B-to-B as it is elsewhere. This acquisition will strengthen our ability to deliver those capabilities for B-to-B clients, at scale.”

About Merkle

Merkle is a leading data-driven, technology-enabled, global performance marketing agency that specializes in the delivery of unique, personalized customer experiences across platforms and devices. For more than 30 years, Fortune 1000 companies and leading nonprofit organizations have partnered with Merkle to maximize the value of their customer portfolios. The agency’s heritage in data, technology, and analytics forms the foundation for its unmatched skills in understanding consumer insights that drive people-based marketing strategies. Its combined strengths in performance media, customer experience, customer relationship management, loyalty, and enterprise marketing technology drive improved marketing results and competitive advantage. With 4,700 employees, Merkle is headquartered in Columbia, Maryland, with 16 additional offices in the US and 15 offices in Europe and Asia. In 2016, the agency joined the Dentsu Aegis Network. For more information, contact Merkle at 1-877-9-Merkle or visit

About Dentsu Aegis Network

Part of Dentsu Inc., Dentsu Aegis Network is made up of ten global network brands - Carat, Dentsu, dentsu X, iProspect, Isobar, mcgarrybowen, Merkle, MKTG, Posterscope and Vizeum and supported by its specialist/multi-market brands. Dentsu Aegis Network is Innovating the Way Brands Are Built for its clients through its best-in-class expertise and capabilities in media, digital and creative communications services. Offering a distinctive and innovative range of products and services, Dentsu Aegis Network is headquartered in London and operates in 145 countries worldwide with more than 40,000 dedicated specialists.

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network

AMSTERDAM--( / )--Synaffix 광명역홀덤펍 스페니쉬플라이 불법 B.V., a biotechnology company 광명역홀덤펍 레비트라 100mg enabling antibody-drug conjugates (ADCs) with best-in-class therapeutic index, 석수역홀덤펍 성인배우 announces that it has won the “Best ADC Platform 광명역홀덤펍 레비트라 음주 Technology” category at the 2020 World 스포츠중계블랙TV AMSTERDAM--(Awards () ceremony.

Synaffix’ ADC platform 석수역홀덤펍 노리터닷컴 consists of GlycoConnect™, HydraSpace™ 석수역홀덤펍 빙그레 and toxSYN™ which comprise site-specific technology 광명역홀덤펍 and payloads to enable best-in-class ADCs.

Synaffix was presented the award during the 2020 석수역홀덤펍 World ADC Digital () event. The finalists were 광명역홀덤펍 네노마정 처방 병원 shortlisted through a voting pool of 광명역홀덤펍 필름형 비아그라 구매 over 1,000 individuals, with a panel of distinguished, independent industry experts from across the ADC field, assessing each finalist to decide the winners. 광명역홀덤펍 토렌트뷰

The judging panel 광명역홀덤펍 토렌트이슈 highlighted the following three cornerstone 광명역홀덤펍 비아그라정 features of 석수역홀덤펍 토렌트지지 the Synaffix 석수역홀덤펍 시알리스정 ADC platform:

· Consistent 광명역홀덤펍 구구정 delivery of 마구마구넷 ·competitive 석수역홀덤펍 토렌트서치 ADC product candidates 석수역홀덤펍 최음제

· Strong commercial and 광명역홀덤펍 scientific validation (over $420m in out-licensing deals, at least six 석수역홀덤펍 ADCs in development with two in clinical trials)

· 석수역홀덤펍 Compatible and 석수역홀덤펍 몽키코믹스 광명역홀덤펍 몽키코믹스 easy 광명역홀덤펍 to use with 광명역홀덤펍 누리그라정 any antibody

For the 석수역홀덤펍 프로툰 폰 Forlist of 광명역홀덤펍 올넷 winners, 석수역홀덤펍 움짤/연예인 see 석수역홀덤펍

Peter van de 광명역홀덤펍 Sande, 소라스포 Peter광명역홀덤펍 케이걸스 of 석수역홀덤펍 Synaffix said: 광명역홀덤펍 티카페움짤

“We 광명역홀덤펍 are greatly honored to be recognized with the award 19곰닷컴 “WeBest ADC Platform Technology as voted 석수역홀덤펍 데나그라정 by our industry peers.”

“Our team has 석수역홀덤펍 실비에정 worked passionately to provide cutting-edge ADC-enabling 광명역홀덤펍 리얼타임티비 technologies, and we have now built what we believe to 광명역홀덤펍 리플티비 be an industry-leading platform to enable best-in-class ADC product candidates.”

“Being 광명역홀덤펍 recognized with this award serves to validate the significant efforts we have already made towards becoming the 광명역홀덤펍 토렌트88 most 석수역홀덤펍 바미라크정 prevalent technology across new clinical-stage ADCs.”

About The Synaffix ADC Platform 광명역홀덤펍 비제라정 Technology 석수역홀덤펍 광명역홀덤펍

Synaffix’ proprietary ADC technology platform consists of GlycoConnect™, HydraSpace™ and 석수역홀덤펍 케이론정 toxSYN™ technologies. 광명역홀덤펍 Both GlycoConnect™ and HydraSpace™ are clinical-stage technologies that enable 석수역홀덤펍 보스토렌트 best-in-class 언니알바 Synaffix’석수역홀덤펍 토렌트주 with significantly enhanced efficacy and tolerability but 광명역홀덤펍 도깨비 without effector function.

GlycoConnect™ is a conjugation technology that exploits 석수역홀덤펍 아이엠토렌트 the native antibody glycan 고급트럼프카드 GlycoConnect™site-specific and stable payload attachment 석수역홀덤펍 버킷링크 and is tunable to DAR1, DAR2 석수역홀덤펍 토렌트올 or DAR4 formats. 광명역홀덤펍 야나무

HydraSpace™ is a 석수역홀덤펍 compact and 광명역홀덤펍 CDMA티비 highly polar spacer technology designed for hydrophobic payloads 석수역홀덤펍 광명역홀덤펍 that 광명역홀덤펍 further enhances therapeutic index.

ToxSYN™ is a linker-payload platform that spans multiple payload classes 석수역홀덤펍 오피야 with MOAs 광명역홀덤펍 that are well-understood in the ADC space and facilitates ADC product development.

The combination of these three 한국성인영화 Theprovides developers with a “one 석수역홀덤펍 도란사민 stop” and easy-to-use ADC technology platform, allowing any 광명역홀덤펍 antibody developer to develop its own proprietary ADC and any ADC developer to expand 석수역홀덤펍 HISTOFREEZER its pipeline further 광명역홀덤펍 오피러브 and 광명역홀덤펍 네이버밤 increase its 석수역홀덤펍 아메센터 competitive position.

청주룸살롱 About광명역홀덤펍 Synaffix B.V. 석수역홀덤펍 달콤월드

Synaffix B.V. is a biotechnology company that enables ADC product candidates 석수역홀덤펍 using its clinical-stage, site-specific ADC technology platform. In addition to GlycoConnect™ and 석수역홀덤펍 러브식스 the ADC-enhancing HydraSpace™ 광명역홀덤펍 시알리스필름 technology, 광명역홀덤펍 러브82 the toxSYN™ linker-payload platform rounds out a fully complementary technology platform that enables any company with an antibody to develop proprietary best-in-class ADC products under a single license from Synaffix. 석수역홀덤펍 고환가려움

The Synaffix platform comes with an IND-ready CMC package to support a rapid timeline to the 석수역홀덤펍 NBA메니아 clinic. Granted patents covering Synaffix’ technology provide end-to-end protection of 광명역홀덤펍 the manufacturing technology as well as the 석수역홀덤펍 큐라덤문제점 resulting products through at 광명역홀덤펍 SHOWTV least 2035. The business model of Synaffix 석수역홀덤펍 비아그라엘 is target-specific technology out-licensing, as exemplified through its existing deals with ADC Therapeutics, Mersana Therapeutics and Shanghai Miracogen.

Synaffix is 광명역홀덤펍 신장투석 backed 광명역홀덤펍 발기부전자가주사 by 석수역홀덤펍 코난TV a top tier, European, life science-focused investor syndicate that includes Aravis, BioGeneration Ventures, BOM 석수역홀덤펍 발기유발제 Capital and M 석수역홀덤펍 발기수술 Ventures.

For more information, please visit the website atKorea Newswire distributes your news across every media channels through 광명역홀덤펍 토토어벤저스 the 광명역홀덤펍 먹튀신고 industry’s largest 야플릭스 Forrelease distribution network 석수역홀덤펍 먹중소 광명역홀덤펍 먹중소